Claims for Patent: 7,960,108

Summary for Patent: 7,960,108

Title:	DNA polymorphisms in sterol-regulator-element binding proteins
Abstract:	The invention relates to DNA polymorphisms in sterol regulator element binding proteins (SREBP) that are characteristic of a higher risk of genetic diseases in humans such as hyperchlolesterolemia. The corresponding polymorphisms, especially the polymorphisms on SREBP-1 and SREBP-2 are frequently observed in Alzheimer patients (SREBP-2). They are also characterized by a specific behavior in the therapy of HIV patients with proteas inhibitors and appear to have an influence on the mortality.
Inventor(s):	Miserez; Andre R. (Aesch, CH)
Assignee:
Application Number:	11/787,746
Patent Claims:	1. A method for the detection of at least one of an increased or decreased disease risk, an increased or decreased mortality risk, an increased or decreased sensitivity to a method of therapy or their side effects, comprising taking a blood or a tissue sample, examine said blood or tissue sample for the presence of at least one of the following nucleotide sequences in SREBP-1 exon 18c TABLE-US-00010 GCACCTAGGGAAAGGCTTC, (Seq.Id.No. 3) GCACCTAGGCAAAGGCTTC, (Seq.Id.No. 1) and/or for the presence of at least one of the following nucleotide sequences in SREBP-2 exon 10 TABLE-US-00011 CTGCTGCCGGCAACCTACA, (Seq.Id.No. 7) CTGCTGCCGCCAACCTACA, (Seq.Id.No. 5) wherein in case of SREBP-1 the presence of a polymorphism is determined at nucleic acid level and in case of SREBP-2 at amino acid and/or nucleic acid level. 2. The method of claim 1, wherein said polymorphism shows a recognition site for a cleavage site lying within said polymorphism and wherein said examination is done using said recognition sequence. 3. The method of claim 1, wherein said recognition sequence is a recognition sequence for Xmn I or Msp I i.e GAANNNNTTC or CCGG, wherein N can be any nucleotide. 4. The method of claim 1, wherein the detection of the presence of a polymorphism is done at amino acid level. 5. The method of claim 1, wherein the detection of the presence of a polymorphism is done at nucleic acid level. 6. The method of claim 1, comprising taking a blood or a tissue sample, extracting at least a fragment of the DNA of a SREBP-1 exon 18c comprising the nucleotide sequence TABLE-US-00012 GCACCTAGGGAAAGGCTTC (Seq.Id.No. 3) or GCACCTAGGCAAAGGCTTC, (Seq.Id.No. 1) and/or at least a fragment of SREBP-2 exon 10 comprising the nucleotide sequence TABLE-US-00013 CTGCTGCCGGCAACCTACA (Seq.Id.No. 7) or CTGCTGCCGCCAACCTACA, (Seq.Id.No. 5) amplifying said fragment using two primer oligonucleotide sequences, subjecting the product of said amplification to a digestion with a suitable restriction enzyme or a denaturation, and electrophoretically separating the digestion products or the denaturation products, respectively. 7. The method of claim 6, wherein at least one of said primer oligonucleotide sequences is located in the intron region which is adjacent to the exon where said polymorphism comprising oligonucleotide sequence exists. 8. The method of claim 6, wherein said primer oligonucleotide sequences are selected from the following pairs or from sequences which hybridize to said pairs under stringent conditions: TABLE-US-00014 S1.18cF: (Seq.Id.No. 9) 5'-TTATTTATAATCTGGGTTTTGTGTC-3' and S1.18cR: (Seq.Id.No. 10) 5'-GGGAAGAGCTAAGTTAAAAGTTGTG-3' or EcoR I.S1.18cF: (Seq.Id.No. 11) 5'-CGGAATTCTGAAATTATTTATAATCTGGGTTTTGTGTC-3' and EcoR I.S1.18cR: (Seq.Id.No. 12) 5'-CGGAATTCATCGGGGAAGAGCTAAGTTAAAAGTTGTG-3' or S2.10P.F: (Seq.Id.No. 13) 5'-GCCAGTGACCATTAACACCTTTTGA-3' and S2.10P.R.: (Seq.Id.No. 14) 5'-TCGTCTTCAAAGCCTGCCTCAGTGGCTGGC-3' or EcoRI S2.10F: (Seq.Id.No. 15) 5'-CGGAATTCGCCAGTGACCATTAACACCTTTTGA-3' and EcoRI S2.10R: (Seq.Id.No. 16) 5'-CGGAATTCTGCAGCAAGCCAGTCATCAGCAGCT-3'. 9. A pair of purified oligonucleotides from SREBP-2, exon 10 wherein one of the oligonucleotides comprises the sequence CTGCTGCCGGCAACCTACA (Seq.Id.No.7) and the second oligonucleotide comprises CTGCTGCCGCCAACCTACA (Seq.Id.No. 5). 10. A DNA and/or RNA chip wherein said chip comprises the pair of purified oligonucleotides of claim 9. 11. A purified oligonucleotide from SREBP-2, exon 10 which is 19 to 30 nucleotides in length and which comprises the sequence CTGCTGCCGGCAACCTACA (Seq.Id.No.7). 12. A DNA and/or RNA chip wherein said chip comprises a purified oligonucleotide of claim 11. 13. The DNA and/or the RNA chip of claim 10, further comprising at least one purified oligonucleotide sequence selected from the group consisting of: a sequence from SREBP-1, exon 18c, comprising GCACCTAGGGAAAGGCTTC (Seq.Id.No. 3), a sequence from SREBP-1, exon 18c, comprising GCACCTAGGCAAAGGCTTC (Seq.Id.No. 1 a sequence from SREBP-2, exon 6, comprising CTGAAGAAG, a sequence from SREBP-2, exon 6, comprising CTGAGGAAG, and any combination of two or more of these sequences. 14. The DNA and/or the RNA chip of claim 12, further comprising at least one purified oligonucleotide sequence selected from the group consisting of: a sequence from SREBP-1, exon 18c, comprising GCACCTAGGGAAAGGCTTC (Seq. Id. No. 3), a sequence from SREBP-1, exon 18c, comprising GCACCTAGGCAAAGGCTTC (Seq. Id. No. 1), a sequence from SREBP-2, exon 6, comprising CTGAAGAAG, a sequence from SREBP-2, exon 6, comprising CTGAGGAAG, and any combination of two or more of these sequences. 15. A pair of purified oligonucleotides from SREBP-1, exon 18c wherein one of the oligonucleotides comprises the sequence GCACCTAGGGAAAGGCTTC (Seq.Id.No.3) and the second oligonucleotide comprises the sequence GCACCTAGGCAAAGGCTTC (Seq.Id.No. 1). 16. A DNA and/or RNA chip wherein said chip comprises the pair of purified oligonucleotides of claim 15. 17. The DNA and/or the RNA chip of claim 16 further comprising at least one purified oligonucleotide sequence selected from the group consisting of: a sequence from SREBP-2, exon 10, comprising CTGCTGCCGGCAACCTACA (Seq.Id.No. 7), a sequence from SREBP-2, exon 10, comprising CTGCTGCCGCCAACCTACA (Seq. Id. No. 5), a sequence from SREBP-2, exon 6, comprising CTGAAGAAG, a sequence from SREBP-2, exon 6, comprising CTGAGGAAG, and any combination of two or more of these sequences. 18. A method for the detection of at least one of an increased or decreased disease risk, an increased or decreased mortality risk, an increased or decreased sensitivity to a method of therapy or their side effects, comprising taking a blood or a tissue sample, examine said blood or tissue sample for the presence of at least one of the nucleotide sequences of claim 9, wherein the presence of a polymorphism is determined at amino acid and/or nucleic acid level. 19. The method of claim 9 wherein the examination of the blood sample is done for the presence of one of the nucleotide sequences of claim 9, and the presence of a polymorphism is determined at amino acid and/or nucleic acid level, and also for the presence of one of the nucleotide sequences in SREBP-1 exon 18c TABLE-US-00015 GCACCTAGGGAAAGGCTTC, (Seq.Id.No. 3) GCACCTAGGCAAAGGCTTC, (Seq.Id.No. 1) wherein the presence of a polymorphism is determined at nucleic acid level.

Details for Patent 7,960,108

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2019-07-09
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2019-07-09
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2019-07-09